Changes in expression of imprinted genes following treatment of human cancer cell lines with non-mutagenic or mutagenic carcinogens

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 351-360

  Shibui, Takeo ^a,d   Higo, Yukari ^a   Tsutsui, Takeo W ^a   Uchida, Minoru ^a   Oshimura, Mitsuo ^b   Barrett, J Carl ^c,e   Tsutsui, Takeki ^a  

^a NIPPON DENTAL UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d TOKYO DENTAL COLLEGE   (Japan)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Chemical carcinogens; Epigenetic modification; Human cells; Imprinted genes

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; 5 AZA 2' DEOXYCYTIDINE; AFLATOXIN B1; ARSENITE SODIUM; CARCINOGEN; CHLORPROMAZINE; CYCLOSPORIN A; DIETHYLSTILBESTROL; DIMETHYL SULFOXIDE; GENE PRODUCT; GENOMIC DNA; HISTONE; HISTONE 19; MELPHALAN; MITOMYCIN C; MUTAGENIC AGENT; PROTEIN NDN; PROTEIN PEG 3; PROTEIN SNRPN; PROTEIN ZAC; RESERPINE;

ACETYLATION; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENICITY; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EUCHROMATIN; GENE EXPRESSION; GENOME IMPRINTING; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION;

AUTOANTIGENS; CARCINOGENS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION; GENOMIC IMPRINTING; HUMANS; IMMUNOPRECIPITATION; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEINS, SMALL NUCLEAR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 48749103045     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000015     Document Type: Article

References (43)

1. Murphy SK and Jirtle RL: Imprinted genes as potential genetic and epigenetic toxicologic targets. Environ Health Perspect 108: 5-11, 2000.
2. Hu JF, Vu TH and Hoffman AR: Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271: 18253-18262, 1996.
3. Dean W, Bowden L, Aitchison A, et al: Altered imprinted gene methylation and expression in completely ES cell-derived mouse fetuses: association with aberrant phenotypes. Development 125: 2273-2282, 1998.
4. Humpherys D, Eggan K, Akutsu H, et al: Epigenetic instability in ES cells and cloned mice. Science 293: 95-97, 2001.
5. Rideout WM 3rd, Eggan K and Jaenisch R: Nuclear cloning and epigenetic reprogramming of the genome. Science 293: 1093-1098, 2001.
6. Tycko B: Epigenetic gene silencing in cancer. J Clin Invest 105: 401-407, 2000.
7. Jirtle RL, Sander M and Barrett JC: Genomic imprinting and environmental disease susceptibility. Environ Health Perspect 108: 271-278, 2000.
8. Malik K and Brown KW: Epigenetic gene deregulation in cancer. Br J Cancer 83: 1583-1588, 2000.
9. Schofield PN, Joyce JA, Lam WK, et al: Genomic imprinting and cancer; new paradigms in the genetics of neoplasia. Toxicol Lett 120: 151-160, 2001.
10. Plass C and Soloway PD: DNA methylation, imprinting and cancer. Eur J Hum Genet 10: 6-16, 2002.
11. Feinberg AP, Cui H and Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 12: 389-398, 2002.
12. Feinberg AP, Oshimura M and Barrett JC: Epigenetic mechanisms in human disease. Cancer Res 62: 6784-6787, 2002.
13. Ashby J, De Serres FJ, Draper M, et al: Evaluation of short-term tests for carcinogenesis: Report of the International Programme on Chemical Safety's Collaborative Study on In Vitro Assays, Progress in mutation research. Vol 5. Elsevier Science Publishers, Amsterdam, 1985.
14. Maegawa S, Yoshioka H, Itaba N, et al: Epigenetic silencing of PEG3 gene expression in human glioma cell lines. Mol Carcinog 31: 1-9, 2001.
15. Bai L, Mihara K, Kondo Y, Honma M and Namba M: Immortalization of normal human fibroblasts by treatment with 4-nitroquinoline 1-oxide. Int J Cancer 53: 451-456, 1993.
16. 1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome. Carcinogenesis 16: 25-34, 1995.
17. Tsutsui TW, Inaba T, Fisher LW, Robey PG and Tsutsui T: In vitro chromosome aberration tests using human dental pulp cells to detect the carcinogenic potential of chemical agents. Odontology 94: 44-50,2006.
18. INK4a and pRb inactivation with immortalization of human cells. Carcinogenesis 23: 2111-2117, 2002.
19. Kumakura S, Tsutsui TW, Yagisawa J, Barrett JC and Tsutsui T: Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res 65: 2778-2786, 2005.
20. Xin Z, Allis CD and Wagstaff J: Parent-specific complementary patterns of histone H3 lysine 9 and H3 lysine 4 methylation at the Prader-Willi syndrome imprinting center. Am J Hum Genet 69: 1389-1394, 2001.
21. Chen H, Ke Q, Kluz T, Yan Y and Costa M: Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol Cell Biol 26: 3728-3737, 2006.
22. Saitoh S and Wada T: Parent-of-origin specific histone acetylation and reactivation of a key imprinted gene locus in Prader-Willi syndrome. Am J Hum Genet 66: 1958-1962, 2000.
23. Boggs BA, Cheung P, Heard E, Spector DL, Chinault AC and Allis CD: Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nat Genet 30: 73-76, 2002.
24. Peters AH, Mermoud JE, O'Carroll D, et al: Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet 30: 77-80, 2002.
25. Wolffe AP and Matzke MA: Epigenetics: regulation through repression. Science 286: 481-486, 1999.
26. Wolffe AP and Guschin D: Review: chromatin structural features and targets that regulate transcription. J Struct Biol 129: 102-122, 2000.
27. Bird AP and Wolffe AP: Methylation-induced repression-belts, braces and chromatin. Cell 99: 451-454, 1999.
28. Cheung P, Allis CD and Sassone-Corsi P: Signaling to chromatin through histone modifications. Cell 103: 263-271, 2000.
29. Turner BM: Histone acetylation and an epigenetic code. Bioassays 22: 836-845, 2000.
30. Issa JP, Vertino PM, Boehm CD, Newsham IF and Baylin SB: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 93: 11757-11762, 1996.
31. Riesewijk AM, Hu L, Schulz U, et al: Monoallelic expression of human PEG1/MEST is paralleled by parent-specific methylation in fetuses. Genomics 42: 236-244, 1997.
32. Yu Y, Xu F, Peng H, et al: NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96: 214-219, 1999.
33. El Kharroubi A, Piras G and Stewart CL: DNA demethylation reactivates a subset of imprinted genes in uniparental mouse embryonic fibroblasts. J Biol Chem 276: 8674-8680, 2001.
34. Ghoshal K, Datta J, Majumder S, et al: 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727-2741, 2005.
35. Jones PL, Veenstra GJ, Wade PA, et al: Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19: 187-191, 1998.
36. Nakayama J, Rice JC, Strahl BD, Allis CD and Grewal SI: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110-113, 2001.
37. Poll EH, Arwert F, Kortbeek HT and Eriksson AW: Fanconi anaemia cells are not uniformly deficient in unhooking of DNA interstrand crosslinks, induced by mitomycin C or 8-methoxypsoralen plus UV A. Hum Genet 68: 228-234, 1984.
38. Li S, Hansman R, Newbold R, Davis B, McLachlan JA and Barrett JC: Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Mol Carcinog 38: 78-84, 2003.
39. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K and Hirano S: Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 37: 298-311, 2006.
40. Zhao CQ, Young MR, Diwan BA, Coogan TP and Waalkes MP: Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94: 10907-10912, 1997.
41. Takahashi M, Barrett JC and Tsutsui T: Transformation by inorganic arsenic compounds of normal Syrian hamster embryo cells into a neoplastic state in which they become anchorage-independent and cause tumors in newborn hamsters. Int J Cancer 99: 629-634, 2002.
42. Costa M, Sutherland JE, Peng W, Salnikow K, Broday L and Kluz T: Molecular biology of nickel carcinogenesis. Mol Cell Biochem 222: 205-211, 2001.
43. Broday L, Peng W, Kuo MH, Salnikow K, Zoroddu M and Costa M: Nickel compounds are novel inhibitors of histone H4 acetylation. Cancer Res 60: 238-241, 2000.